Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Phase 2 Completed 56 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Novartis Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

This research is being done to determine if combining an investigational drug called Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose chemotherapy.

Timeline

Start: 2012-09
Primary completion: 2017-10
Completion: 2020-08

Publications

Results Schoch LK, Asiama A, Zahurak M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, Gladstone DE. Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients. Cancer Chemother Pharmacol. 2018 Feb;81(2):347-354. doi: 10.1007/s00280-017-3499-y. Epub 2017 Dec 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	2.5 mg	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous

Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma

Summary

Timeline

Publications

Drugs

Indications